In silico design of clinical trials: a method coming of age.
OBJECTIVE
To determine the feasibility and potential usefulness of mathematical models in evaluating immunomodulatory strategies in clinical trials of severe sepsis.


METHODS
Mathematical modeling of immunomodulation in simulated patients.


METHODS
Computer laboratory.


RESULTS
We introduce and evaluate the concept of conducting a randomized clinical trial in silico based on simulated patients generated from a mechanistic mathematical model of bacterial infection, the acute inflammatory response, global tissue dysfunction, and a therapeutic intervention. Trial populations are constructed to reflect heterogeneity in bacterial load and virulence as well as propensity to mount and modulate an inflammatory response. We constructed a cohort of 1,000 trial patients submitted to therapy with one of three different doses of a neutralizing antibody directed against tumor necrosis factor (anti-TNF) for 6, 24, or 48 hrs. We present cytokine profiles over time and expected outcome for each cohort. We identify subgroups with high propensity for being helped or harmed by the proposed intervention and identify early serum markers for each of those subgroups. The mathematical simulation confirms the inability of simple markers to predict outcome of sepsis. The simulation clearly separates cases with favorable and unfavorable outcome on the basis of global tissue dysfunction. Control survival was 62.9% at 1 wk. Depending on dose and duration of treatment, survival ranged from 57.1% to 80.8%. Higher doses of anti-TNF, although effective, also result in considerable harm to patients. A statistical analysis based on a simulated cohort identified markers of favorable or adverse response to anti-TNF treatment.


CONCLUSIONS
A mathematical simulation of anti-TNF therapy identified clear windows of opportunity for this intervention as well as populations that can be harmed by anti-TNF therapy. The construction of an in silico clinical trial could provide profound insight into the design of clinical trials of immunomodulatory therapies, ranging from optimal patient selection to individualized dosage and duration of proposed therapeutic interventions.
Clermont
Gilles
G
Department of Critical Care Medicine and Clinical Research, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Bartels
John
J
Kumar
Rukmini
R
Constantine
Greg
G
Vodovotz
Yoram
Y
Chow
Carson
C
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001424:Bacterial Infections / Q000150:complications / Q000276:immunology; D002986:Clinical Trials as Topic; D015331:Cohort Studies; D003198:Computer Simulation; D005240:Feasibility Studies; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D008962:Models, Theoretical; D018746:Systemic Inflammatory Response Syndrome / Q000188:drug therapy* / Q000276:immunology* / Q000382:microbiology; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000276:immunology
D000911:Antibodies, Monoclonal; D007155:Immunologic Factors; D014409:Tumor Necrosis Factor-alpha